MaxCyte Reports Q4 2025 Earnings: Revenue Down 15%, Core Revenue Diversification Improves
ByAinvest
Tuesday, Mar 24, 2026 5:31 pm ET1min read
MXCT--
MaxCyte (MXCT) reported Q4 2025 revenue of $7.3 million, a 16% decline from the prior year. Total 2025 revenue was $33 million, down 15% from 2024. The company expects $4 million in core revenue headwinds in 2026 due to SPL program discontinuations and a major customer's reorganization. Revenue guidance for 2026 is between $30 million and $32 million, with a cash position of at least $136 million at the end of 2026.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet